Drug Profile
Research programme: neurological therapies - Eisai/Johns Hopkins University
Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Johns Hopkins Brain Science Institute
- Developer Eisai Inc; Johns Hopkins Brain Science Institute
- Class Neuroprotectants; Small molecules
- Mechanism of Action Glutamate carboxypeptidase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Neurological-disorders in USA
- 31 May 2017 Small molecule glutamate carboxypeptidase II (GCPII) inhibitors is still in early research for Neurological disorders in USA
- 31 May 2017 Small molecule glutamate carboxypeptidase II inhibitors licensed to Eisai for Neurological disorders